United Therapeutics

UTHR

Market cap $25.8B

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that the U.S. Food and Drug Administration (FDA) has granted Regenerative Medicine Advanced Therapy (RMAT) designation to the company's investigational miroliverELAP®, an external liver assist product. Developed by Miromatrix Medical Inc., a wholly owned subsidiary of United Therapeutics, miroliverELAP consists of an external blood cir.

United Therapeutics (UTHR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Investors interested in stocks from the Medical - Drugs sector have probably already heard of Catalyst Pharmaceutical (CPRX) and United Therapeutics (UTHR). But which of these two stocks offers value investors a better bang for their buck right now?

United Therapeutics Corporation maintains a Strong Buy rating after a second phase 3 win for nebulized Tyvaso in idiopathic pulmonary fibrosis [IPF]. UTHR achieved superior FVC improvement in TETON-1 [130.1 mL] versus TETON-2 [95.6 mL], both statistically significant, supporting sNDA submission for IPF by summer of this year. Priority Review will be sought for Tyvaso in IPF, with further expansion targeted via ongoing TETON-PPF for progressive pulmonary fibrosis.

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

United Therapeutics jumps 12.5% as phase III TETON-1 data show strong lung function gains for Tyvaso in IPF, paving the way for a potential FDA filing.

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

United Therapeutics (NASDAQ:UTHR) surged more than 12% in pre-market trading on March 30 after positive TETON-1 trial data triggered price target raises from two major Wall Street firms.

United Therapeutics (UTHR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Shares of United Therapeutics Corporation (NASDAQ:UTHR) jumped more than 13% on Monday morning following the announcement of positive topline results from the Phase 3 TETON‑1 trial of its inhaled therapy, Tyvaso, in idiopathic pulmonary fibrosis (IPF). Jefferies analysts called the results “highly clinically meaningful,” noting that the trial met its primary endpoint with a change in absolute forced vital capacity (FVC) of 130.1 milliliters at week 52 compared with placebo (p